Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

X
Drug Profile

ION 224

Alternative Names: ION-224; IONIS-DGAT2Rx; ISIS 484137; ISIS-DGAT2Rx

Latest Information Update: 19 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides; Hepatoprotectants
  • Mechanism of Action Diacylglycerol O-acyltransferase inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis

Most Recent Events

  • 13 Mar 2024 Efficacy and adverse event data from phase II trial in Non-alcoholic steatohepatitis released by Ionis Pharmaceuticals
  • 28 Feb 2024 Ionis Pharmaceuticals completes a phase-II trial in Non-alcoholic steatohepatitis (In adults, In the elderly) in USA and Puerto Rico (SC, Injection) (NCT04932512)
  • 01 Jul 2021 Phase-II clinical trials in Non-alcoholic steatohepatitis (In adults, In elderly) in USA (SC) (NCT04932512)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days